Facebook
X
LinkedIn
Forward
Practical Management Strategies for Advanced Stage Gynecologic Cancer Patients
For the practical radiation oncology program, this activity includes three speakers for education on the following complex presentations for managing advanced stage gynecologic cancer patients. 1) Kevin Albuquerque, MD Radiotherapy across the spectrum of metastatic GYN malignancies: A case-based discussion of the definitive management strategies for oligometastatic cervical cancer and the role of SBRT/high dose RT in oligometastatic, oligoprogressive, and bulky pelvic tumors in GYN malignancies. 2) Dominique Rash, MD Salvaging the primary: definitive reirradiation or palliation? A case-based discussion of the considerations and calculations that are performed when addressing central recurrences following initial pelvic radiation with either external beam radiation or combined EBRT and brachytherapy. This includes a discussion of the goal EQD2 doses for both the target volumes and the organs at risk, and the additional challenges of approaching such patients in the context of recent systemic therapy advances. 3) Sage Bolte, PhD Management of sexual side effects of radiotherapy and progressive disease for the advanced stage patient: A certified sex therapist provides practical recommendations for counseling and resources for patients suffering from side effects of progressive cancer and therapy with respect to sexual health and menopause symptoms.
Topics:
- Radiotherapy Across the Spectrum of Metastatic GYN Malignancies
Kevin V. Albuquerque, MD - Salvaging the Primary: Definitive Reirradiation or Palliation?
Dominique L. Rash, MD - Management of Sexual Side Effects of Radiotherapy and Progressive Disease for the Advanced Stage Patient
Sage Bolte, PhD - Q and A
Avani Dholakia Rao, MD - Moderator
Full Panel
This activity is available from March 3, 2026, through 11:59 p.m. Eastern time on March 2, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, nurses and radiation dosimetrists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Approach a patient with oligometastatic cervical and endometrial cancer with a strategy that expands upon palliation.
- Consider the approach to reirradiation for patients with GYN malignancies.
Moderator:
- Avani Dholakia Rao, MD, is employed by Inova Schar Cancer Institute. Dr. Rao receives grant/research funding from Ion Beam Applications.
Speakers:
- Kevin V. Albuquerque, MD, is employed by University of Texas Southwestern Medical Center. Dr. Albuquerque has no relevant financial relationship with ineligible companies to disclose.
- Dominique L. Rash, MD, is employed by INOVA Health Foundation. Dr. Rash has no relevant financial relationship with ineligible companies to disclose.
- Sage Bolte, PhD, is employed by INOVA Health Foundation. Dr. Bolte has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until March 2, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.